Glen P Westall
Overview
Explore the profile of Glen P Westall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gardiner B, Westall G, Sester M, Torre-Cisneros J, Kotton C
Transplantation
. 2025 Feb;
109(3):395-398.
PMID: 39968631
No abstract available.
2.
ODonnell J, Hastings L, Briody J, Chan C, Colombo C, Douglas T, et al.
Pediatr Pulmonol
. 2025 Feb;
59(6):1661-1676.
PMID: 39903130
Background: Cystic fibrosis (CF) is a life-shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF-related lung disease, with...
3.
Westall G, Gottlieb D, Hughes P, Marinelli T, Rawlinson W, Ritchie D, et al.
Intern Med J
. 2024 Dec;
55(1):12-19.
PMID: 39620697
Cytomegalovirus (CMV) infections continue to be associated with significant morbidity and mortality following solid organ transplantation and haemopoietic stem cell transplantation. Advances in understanding the biology of CMV in the...
4.
Darie A, Levvey B, Shingles H, Paraskeva M, Levin K, Ennis S, et al.
J Heart Lung Transplant
. 2024 Nov;
PMID: 39536921
Background: Although the demand for allografts continuously surpasses the supply, the majority of lungs offered for transplant are declined based on various factors, including donor age. This in turn sustains...
5.
Hiho S, Levvey B, Diviney M, Brooks A, Holdsworth R, Snell G, et al.
HLA
. 2024 Jun;
103(6):e15544.
PMID: 38924641
HLA (HLA) are a major barrier to transplant success, as HLA-A and -B molecules are principal ligands for T-cells, and HLA-C for Killer cell Immunoglobulin-like Receptors (KIR), directing Natural Killer...
6.
Birnie J, Ahmed T, Kidd S, Westall G, Snell G, Peleg A, et al.
J Fungi (Basel)
. 2024 Feb;
10(2).
PMID: 38392766
can cause different clinical manifestations/phenotypes in lung transplant (LTx) recipients and patients with chronic respiratory diseases. It can also precipitate chronic lung allograft dysfunction (CLAD) in LTx recipients. Many host...
7.
Pattaroni C, Begka C, Cardwell B, Jaffar J, Macowan M, Harris N, et al.
Clin Transl Immunology
. 2024 Jan;
13(1):e1485.
PMID: 38269243
Objectives: Idiopathic pulmonary fibrosis (IPF) is a devastating progressive interstitial lung disease with poor outcomes. While decades of research have shed light on pathophysiological mechanisms associated with the disease, our...
8.
Jalali S, Stankovic S, Westall G, Reading P, Sullivan L, Brooks A
Transpl Immunol
. 2023 Nov;
82:101962.
PMID: 38007172
Background: Human natural killer (NK) cells and gamma delta (γδ) T cells may impact outcomes of solid organ transplantation (SOT) such as lung transplantation (LTx) following the differential engagement of...
9.
Westall G, Barnes H, Levin K, Gaffney N, Harris J, Martinez O, et al.
J Heart Lung Transplant
. 2023 Nov;
43(4):571-579.
PMID: 38000763
Background: Optimizing donor use and achieving maximal survival following lung transplantation (LTx) require a pretransplant assessment that identifies clinical, physiological, and psychosocial patient factors associated with both poor and optimal...
10.
Hiho S, Levvey B, Diviney M, Snell G, Sullivan L, Westall G
Am J Transplant
. 2023 Nov;
24(5):827-838.
PMID: 37981213
Outcomes after lung transplantation (LTx) remain poor, despite advances in sequencing technology and development of algorithms defining immunologic compatibility. Presently, there is no consensus regarding the best approach to define...